Joint Efforts for AIDS Prevention & Control: Belt and Road Countries Visit LivzonDx

Time：2026-06-11

1. Gathering at LivzonDx to Deepen International Public Health Exchanges

To support the Belt and Road Initiative and strengthen technical exchange and practical cooperation with participating countries in public health, HIV/AIDS prevention and control, and in vitro diagnostics (IVD), a delegation from the Seminar on New Advances in HIV/AIDS Treatment for Belt and Road Countries recently visited Zhuhai Livzon Diagnostics Inc. (LivzonDx) for a three-day study and exchange program. The delegation consisted of 25 healthcare professionals from seven African countries.

Focusing on recent advances in HIV/AIDS prevention, diagnosis, and treatment, the program featured thematic lectures, site visits, and discussion sessions. It provided a platform for participants to gain insights into China's public health system development, the application of HIV IVD technologies, and the development of the country's pharmaceutical and healthcare sectors.

During the program, Ms. Lin Yan, General Manager of LivzonDx, and Mr. Zhu Weidong, Executive Deputy General Manager, extended a warm welcome to the delegation on the behalf of the company. Led by Mr. Justin Zhang, Director of Strategy, the participants toured the company's exhibition hall, where they received a comprehensive introduction to LivzonDx's development history, core technology platforms, product portfolio, and progress in international expansion. The visit gave them a deeper understanding of the company's innovative practices in in the fields of infectious diseases and public health.

2. Sharing China’s Experience to Strengthen Laboratory Capacity Building

As part of the exchange program, LivzonDx invited Director Zhou Lanlan, an expert from the Zhuhai Center for Disease Control and Prevention (Zhuhai CDC), to deliver a specialized training session on HIV Testing Laboratory Management. The session provided a systematic overview of laboratory management systems, testing procedure standardization, quality control, biosafety management, and practical experiences from Zhuhai.

The training highlighted China’s experience and achievements in the standardized development and operation of HIV testing laboratories, offering participants valuable insights into the country’s HIV testing service system and laboratory management practices. Delegates actively joined the discussion, showing strong interest in China’s public health laboratory capacity building and quality management.

3. Advancing HIV Prevention Through Diagnostic Innovation

During a dedicated exchange session, Ms. Saree Ho, International Marketing Manager of LivzonDx, presented the company’s HIV testing products and integrated solutions. She highlighted LivzonDx’s product portfolio, technical advantages, and real-world applications in HIV screening, diagnosis, and viral load monitoring.

Drawing on the current HIV/AIDS prevention and control landscape in their respective countries, participants exchanged views with the LivzonDx team on laboratory capacity needs and testing requirements in primary-level healthcare settings. Through face-to-face interaction, they gained a clearer picture of LivzonDx's technical strength and innovation in public health testing, and expressed strong recognition of the company’s full-scenario HIV solutions.

4. Exploring Community-Level HIV Prevention and Control in Practice

During the seminar, the participants visited the Xiangzhou District Center for Disease Control and Prevention (CDC) in Zhuhai to gain firsthand insights into the development of China’s community-level public health system and its practices in comprehensive HIV/AIDS prevention and control.

The visit was attended by Mr. Ye Zhongwen, Deputy Director of Zhuhai CDC; Mr. Zhou Yi, Director of the HIV/AIDS Prevention and Control Institute at Zhuhai CDC; Mr. Zhou Yong, Member of the Party Leadership Group of Xiangzhou District Health Bureau and Director of Xiangzhou CDC; Deputy Directors He Guilian and Yang Jing of Xiangzhou CDC; as well as heads of relevant departments and representatives of social organizations.

At the Life Health and Safety Experience Hall and the HIV/AIDS Prevention Knowledge Exhibition Area, participants learned about Xiangzhou District’s innovative approaches in health education, services for key populations, collaboration with social organizations, and community mobilization.

In the panel discussion, Director Zhou Yong shared the district’s achievements and practical experience in HIV/AIDS control, focusing on testing network development, advocacy and intervention models, services for key populations, treatment and care systems, and social organization engagement.

Participants then exchanged views with CDC experts from Zhuhai and Xiangzhou on topics such as community-level testing services, the role of social organizations, interventions for key populations, and patient follow-up management — all in the context of their own national HIV/AIDS efforts. The site visit and discussions deepened their understanding of China’s community-level CDC system in comprehensive HIV/AIDS prevention, health education, and community mobilization.

Additionally, Dr. Liu Xi, Director of the Infectious Disease Prevention and Treatment Center at the Fifth Affiliated Hospital, Sun Yat-sen University, introduced practices across the HIV/AIDS continuum of care, including testing and counseling, post-exposure prophylaxis, antiretroviral therapy, follow-up management, health education, and public outreach. Dr. Liu also engaged with participants on topics related to clinical diagnosis, treatment, and the integration of medical and preventive care for HIV/AIDS.

5. Working Together to Advance Global HIV/AIDS Prevention and Control

On the final day of the program, participants visited Livzon Pharmaceutical Group and the Livzon Industrial Park, where they gained a comprehensive view of the Livzon Group’s development history, R&D innovation, global footprint, and achievements in smart manufacturing and quality management systems. The visit gave them a tangible sense of the integrated strengths of Chinese pharmaceutical enterprises in R&D, quality control, and international collaboration.

This exchange further enriched participants’ understanding of China’s IVD industry and public health practices. With many years of experience in HIV testing, LivzonDx has remained focused on the testing needs of both clinical and public health settings, developing comprehensive and highly accurate solutions across the HIV testing pathway. Its product portfolio covers the entire process, from screening and confirmatory testing to co-infection differentiation and treatment response monitoring. This comprehensive portfolio is designed to meet the diverse testing needs of disease control institutions, hospitals, and primary-level healthcare facilities, while offering new perspectives for countries and regions seeking to strengthen HIV testing capacity and improve laboratory service systems.

As one of China's earliest R&D, manufacturing, and sales enterprises in the HIV IVD market, LivzonDx has established a strong position in HIV viral load testing through reliable product quality and a comprehensive product portfolio:

a. >35% market share in China – ranking first among domestic brands, and the only high-throughput domestic platform used by the China CDC Reference Laboratory and West China Hospital.
b. First domestic viral load assay to receive funding from the Gates Foundation, advancing WHO Prequalification (PQ).
c. First domestic internal standard-based quantitative assay, traceable to WHO international standards.
d. First domestic single-use, fully lyophilized reagent – with a shelf life of ≥2 years.
e. Wide quantitative linear range: 17.6 – 5.8×10⁷ copies/mL.

Moving forward, LivzonDx will continue to leverage the healthcare strengths of Livzon Group, stay focused on global public health needs, and actively promote the adoption of high-quality diagnostic products and total solutions in more countries and regions. It aims to further contribute to enhancing disease testing capabilities, improving access to medical resources, and supporting the global fight against HIV/AIDS.